CN108783456A - A kind of functional food and preparation method thereof of protection and regulating gastointestinal function - Google Patents
A kind of functional food and preparation method thereof of protection and regulating gastointestinal function Download PDFInfo
- Publication number
- CN108783456A CN108783456A CN201810509234.7A CN201810509234A CN108783456A CN 108783456 A CN108783456 A CN 108783456A CN 201810509234 A CN201810509234 A CN 201810509234A CN 108783456 A CN108783456 A CN 108783456A
- Authority
- CN
- China
- Prior art keywords
- parts
- extract
- functional food
- group
- orange peel
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000013376 functional food Nutrition 0.000 title claims abstract description 71
- 230000004224 protection Effects 0.000 title claims abstract description 20
- 230000001105 regulatory effect Effects 0.000 title claims abstract description 20
- 238000002360 preparation method Methods 0.000 title claims description 19
- 239000000284 extract Substances 0.000 claims abstract description 66
- 235000001188 Peltandra virginica Nutrition 0.000 claims abstract description 21
- 235000008599 Poria cocos Nutrition 0.000 claims abstract description 21
- 244000248825 Peltandra virginica Species 0.000 claims abstract description 20
- 229940013712 pineapple extract Drugs 0.000 claims abstract description 20
- 239000002994 raw material Substances 0.000 claims abstract description 19
- 235000020717 hawthorn extract Nutrition 0.000 claims abstract description 18
- 239000002775 capsule Substances 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 239000000463 material Substances 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 238000007873 sieving Methods 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 230000001954 sterilising effect Effects 0.000 claims description 3
- 241001092040 Crataegus Species 0.000 claims description 2
- 235000009917 Crataegus X brevipes Nutrition 0.000 claims description 2
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 claims description 2
- 235000009685 Crataegus X maligna Nutrition 0.000 claims description 2
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 claims description 2
- 235000009486 Crataegus bullatus Nutrition 0.000 claims description 2
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 claims description 2
- 235000009682 Crataegus limnophila Nutrition 0.000 claims description 2
- 235000004423 Crataegus monogyna Nutrition 0.000 claims description 2
- 235000002313 Crataegus paludosa Nutrition 0.000 claims description 2
- 235000009840 Crataegus x incaedua Nutrition 0.000 claims description 2
- 238000000605 extraction Methods 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- 244000197580 Poria cocos Species 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 abstract description 31
- 230000002496 gastric effect Effects 0.000 abstract description 10
- 230000000694 effects Effects 0.000 abstract description 9
- 230000029087 digestion Effects 0.000 abstract description 8
- 239000003814 drug Substances 0.000 abstract description 6
- 230000027119 gastric acid secretion Effects 0.000 abstract description 5
- 230000001175 peptic effect Effects 0.000 abstract description 5
- 229940079593 drug Drugs 0.000 abstract description 4
- 231100000252 nontoxic Toxicity 0.000 abstract description 4
- 230000003000 nontoxic effect Effects 0.000 abstract description 4
- 208000017667 Chronic Disease Diseases 0.000 abstract description 3
- 230000008855 peristalsis Effects 0.000 abstract description 3
- 230000002195 synergetic effect Effects 0.000 abstract description 3
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- 230000000052 comparative effect Effects 0.000 description 37
- 241000699666 Mus <mouse, genus> Species 0.000 description 24
- 230000006870 function Effects 0.000 description 23
- 238000002474 experimental method Methods 0.000 description 14
- 235000013305 food Nutrition 0.000 description 14
- VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 description 13
- 239000013641 positive control Substances 0.000 description 11
- 238000003304 gavage Methods 0.000 description 10
- 206010061218 Inflammation Diseases 0.000 description 9
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 9
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 description 9
- 235000001727 glucose Nutrition 0.000 description 9
- 230000004054 inflammatory process Effects 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 8
- 102100022397 Nitric oxide synthase, brain Human genes 0.000 description 8
- 101710111444 Nitric oxide synthase, brain Proteins 0.000 description 8
- 230000030136 gastric emptying Effects 0.000 description 8
- 239000008103 glucose Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 239000000976 ink Substances 0.000 description 7
- 210000000813 small intestine Anatomy 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 210000000936 intestine Anatomy 0.000 description 6
- 210000001187 pylorus Anatomy 0.000 description 6
- 102000057297 Pepsin A Human genes 0.000 description 5
- 108090000284 Pepsin A Proteins 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 230000034994 death Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 229940111202 pepsin Drugs 0.000 description 5
- 208000007882 Gastritis Diseases 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000004040 coloring Methods 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 210000002249 digestive system Anatomy 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 238000007689 inspection Methods 0.000 description 4
- 230000033001 locomotion Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 208000012895 Gastric disease Diseases 0.000 description 3
- 238000012449 Kunming mouse Methods 0.000 description 3
- 101100451434 Mus musculus Hp gene Proteins 0.000 description 3
- 235000019647 acidic taste Nutrition 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 210000004051 gastric juice Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 241000234671 Ananas Species 0.000 description 2
- 235000007119 Ananas comosus Nutrition 0.000 description 2
- 229930003347 Atropine Natural products 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 229960000396 atropine Drugs 0.000 description 2
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 2
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 2
- 239000004327 boric acid Substances 0.000 description 2
- 210000002318 cardia Anatomy 0.000 description 2
- 229940126678 chinese medicines Drugs 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 210000001156 gastric mucosa Anatomy 0.000 description 2
- 230000007661 gastrointestinal function Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- KJFMBFZCATUALV-UHFFFAOYSA-N phenolphthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2C(=O)O1 KJFMBFZCATUALV-UHFFFAOYSA-N 0.000 description 2
- 230000001141 propulsive effect Effects 0.000 description 2
- 229960000620 ranitidine Drugs 0.000 description 2
- 238000012134 rapid urease test Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- RDEIXVOBVLKYNT-HDZPSJEVSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-[(1r)-1-aminoethyl]oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;(2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(aminomethyl)oxan-2 Chemical compound OS(O)(=O)=O.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@@H](CN)O2)N)[C@@H](N)C[C@H]1N.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@H](O2)[C@@H](C)N)N)[C@@H](N)C[C@H]1N.O1[C@H]([C@@H](C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N RDEIXVOBVLKYNT-HDZPSJEVSA-N 0.000 description 1
- BUCXEFZXWKUCCY-UHFFFAOYSA-N 4-methyl-3-(2-phenylethyl)-1,2,4-oxadiazol-5-one Chemical compound O1C(=O)N(C)C(CCC=2C=CC=CC=2)=N1 BUCXEFZXWKUCCY-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 206010070840 Gastrointestinal tract irritation Diseases 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical group O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- VLQGDKKHHCKIOJ-UHFFFAOYSA-N NNOS Chemical compound NNOS VLQGDKKHHCKIOJ-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010058667 Oral toxicity Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 108010046334 Urease Proteins 0.000 description 1
- 241001251949 Xanthium sibiricum Species 0.000 description 1
- HOBWAPHTEJGALG-JKCMADFCSA-N [(1r,5s)-8-methyl-8-azoniabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenylpropanoate;sulfate Chemical compound [O-]S([O-])(=O)=O.C([C@H]1CC[C@@H](C2)[NH+]1C)C2OC(=O)C(CO)C1=CC=CC=C1.C([C@H]1CC[C@@H](C2)[NH+]1C)C2OC(=O)C(CO)C1=CC=CC=C1 HOBWAPHTEJGALG-JKCMADFCSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 229960001931 ampicillin sodium Drugs 0.000 description 1
- KLOHDWPABZXLGI-YWUHCJSESA-M ampicillin sodium Chemical compound [Na+].C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C([O-])=O)(C)C)=CC=CC=C1 KLOHDWPABZXLGI-YWUHCJSESA-M 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 229960002028 atropine sulfate Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000000080 chela (arthropods) Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000023652 chronic gastritis Diseases 0.000 description 1
- 229940106154 cocklebur extract Drugs 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000000254 damaging effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 230000002183 duodenal effect Effects 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 239000000446 fuel Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000002304 glucoses Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 230000001744 histochemical effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 230000008991 intestinal motility Effects 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004682 mucosal barrier function Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 231100000150 mutagenicity / genotoxicity testing Toxicity 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 238000011017 operating method Methods 0.000 description 1
- 231100000418 oral toxicity Toxicity 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 238000002229 photoelectron microspectroscopy Methods 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000037152 sensory function Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000007447 staining method Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000004260 weight control Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/734—Crataegus (hawthorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9064—Amomum, e.g. round cardamom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
The present invention provides a kind of protection and the functional food of regulating gastointestinal function is made in terms of mass parts by the raw material including following components：5~20 parts of 10~40 parts of orange peel extract, 10~40 parts of tuckahoe extracts, 10~30 parts of Fructus Amomi extract, 10~30 parts of haw thorn extract and pineapple extract.The functional food of the present invention is by combining the orange peel extract of specific proportioning, tuckahoe extracts, Fructus Amomi extract, haw thorn extract and pineapple extract; synergistic effect is played each other; obtain the functional food with protection and regulating gastointestinal function; its is nontoxic; adjustable user's gastric acid secretion; enhance peptic activity of stomach; enhance digestion power; promote gastrointestinal peristalsis; reduce the dependence and use to drug; to reduce the toxic side effect of drug, people's lives quality is improved, the incidence of chronic disease is reduced.
Description
Technical field
The present invention relates to field of functional food, more particularly, to a kind of functionality of protection and regulating gastointestinal function
Food and preparation method thereof.
Background technology
The nutrition that human body needs almost is required for by stomach and intestine, and stomach and intestine, which become, digests most important organ.Life is be unable to do without
Diet, diet be unable to do without digestion.Digestion is the means that human body draws various nutrition, and digestive system is the processing for manufacturing life fuel
Factory.
The factors assessment result for influencing human health is shown in recent years according to the World Health Organization (WHO)：Because of diet, battalion
The harm of the Factors on Human body health such as foster, digestion, accounts for about overall 13%, and it is strong to human body that it is only second to inherent cause (accounting for 15%)
The influence of health.So digestive system --- gastrointestinal function should cause our enough attention.It is worth mentioning that with year
The growth in age, digestive system can also fail, and people to old digestive system decline, gastrointestinal function weakens very common.In the course of time,
Malnutrition, physically-draining, Abwehrkraft des Koepers can be caused to reduce, be susceptible to suffer from digestive disease or various other diseases.The hair of chronic disease
The raw relationship very " intimate " with stomach.
Functional food refer to have trophic function, sensory function and adjust physiological activity function food, including：Enhancing
The food of human body constitution (enhancing immunocompetence, activation lymphatic system etc.)；Prevent disease (hypertension, diabetes, coronary heart disease, just
Secret and tumour etc.) food；It gets well the food of (control cholesterol prevents platelet aggregation, adjusts hematopoiesis function etc.)；It adjusts
Save the food of the food and anti-aging of body rhythms (nerve center, nerve ending, intake and absorption function etc.).Functionality food
The research and development of product still belong to new branch of science and field in China, are the products of multidisciplinary, multi-field continuous mixing together, are related to
Nutrition, pharmacy, physiology, preventive medicine, bioengineering, Food Science.
Therefore, it is very urgent with the functional food of regulating gastointestinal function to develop safely and effectively protection, is not only in that guarantor
Shield and regulating gastointestinal function itself, also reside in the morbidity and mortality of overall reduction chronic disease.
Invention content
In view of the problems of the existing technology, the present invention provide it is a kind of protection and regulating gastointestinal function functional food and
Preparation method, functional food of the invention can adjust gastric acid secretion, enhance peptic activity of stomach, enhance digestion power, promote
Into gastrointestinal peristalsis, protection and regulating gastointestinal function.
The present invention provides a kind of functional food of protection and regulating gastointestinal function, in terms of mass parts, by including with the following group
The raw material divided is made：10~40 parts of orange peel extract, 10~40 parts of tuckahoe extracts, 10~30 parts of Fructus Amomi extract, hawthorn carry
Take 5~20 parts of 10~30 parts of object and pineapple extract.
In above-mentioned technical proposal, by by the orange peel extract of specific proportioning, tuckahoe extracts, Fructus Amomi extract, hawthorn
Extract and pineapple extract combination, play synergistic effect each other, obtain the functionality with protection and regulating gastointestinal function
Food, it is nontoxic, user's gastric acid secretion is adjusted, enhances peptic activity of stomach, inhibits Hp (helicobacter pylori), increases
Strong digestion power promotes gastrointestinal peristalsis.
Preferably, the functional food is made in terms of mass parts by the raw material including following components：Orange peel extract
20~40 parts, 20~40 parts of tuckahoe extracts, 15~25 parts of Fructus Amomi extract, 10~20 parts of haw thorn extract and pineapple extract
5~10 parts.
Preferably, the functional food is made in terms of mass parts by the raw material including following components：Orange peel extract
25~35 parts, 25~35 parts of tuckahoe extracts, 18~22 parts of Fructus Amomi extract, 10~13 parts of haw thorn extract and pineapple extract
8~13 parts.
Preferably, the raw material is carried by orange peel extract, tuckahoe extracts, Fructus Amomi extract, haw thorn extract and pineapple
Object is taken to form.
Preferably, the dosage form of the functional food is capsule, tablet or electuary.
These three above dosage form stabilities of selection are good, and manufacturing cost is relatively low, take with it is easy to carry.Capsule is oral
Afterwards in the disintegration time of gastrointestinal tract than very fast, general 5~10 minutes, GI irritation was small, it is not easy to generate damage to gastric mucosa；
Tablet active constituent is high, and bioavilability is high；It can quickly be dissolved and absorbed after granule is oral, it is in good taste, it is suitble to different crowd.
The present invention also provides a kind of preparation methods of above-mentioned functional food, including：Each component is mixed according to the ratio,
Drying, sterilizing crush and cross 60~100 mesh sieve, and target formulation finally is made in sieving gained fine powder.
Above-mentioned preparation method is simple for process, and will be preferably minimized on the influence of the active constituent of each raw material component, makes obtained
Product efficacy is best.
Preferably, water content is 10wt%~20wt% before each component is mixed.
Preferably, each component mixed, dry after water content be 4wt%~7wt%.
Within the above range by water content control, ensure that mobility of particle is good, convenient for tabletting, filling capsule, packing particle
When Weight control, loading amount error is small.
Preferably, the drying and described sterilize in microwave frequency are 2.45GHz ± 25MHz, and temperature is 60~80 DEG C of items
It is carried out under part.It can achieve the effect that preferably to dry and sterilize in this way, and ensure that product efficacy is unaffected.
Preferably, the sieving was 80 mesh sieve.
The functional food of the present invention is by by the orange peel extract of specific proportioning, tuckahoe extracts, Fructus Amomi extract, mountain
Short, bristly hair or beard extract and pineapple extract combination, play synergistic effect each other, obtain having the function of protection and regulating gastointestinal function
Property food, it is nontoxic, user gastric acid secretion is adjusted, enhances peptic activity of stomach, enhances digestion power, promotes stomach and intestine
It wriggles, reduces the dependence and use to drug, to reduce the toxic side effect of drug, improve people's lives quality, reduce slow
The incidence of property disease.
Specific implementation mode
With reference to specific embodiment, the specific implementation mode of the present invention is described in further detail.Following embodiment
For illustrating the present invention, but it is not limited to the scope of the present invention.
Embodiment 1
The present embodiment provides a kind of functional foods of protection and regulating gastointestinal function, in terms of mass parts, by following raw material
It is made：30 parts of orange peel extract, 30 parts of tuckahoe extracts, 20 parts of Fructus Amomi extract, 10 parts of haw thorn extract and pineapple extract
10 parts.Five kinds of raw materials are purchased from Xi'an day Biotechnology Ltd., similarly hereinafter.
The present embodiment also provides the preparation method of above-mentioned functional food, including：(Q/WHF 0065S- will first be complied with standard
It is quality standard in 2015, the same below) orange peel extract, tuckahoe extracts, Fructus Amomi extract, haw thorn extract and pineapple extraction
Object is stirred evenly as in said ratio input blender, and it is 10wt%~20wt% to control raw material moisture content；It again will mixing
Good material is uniformly laid in by the thickness of 2~2.5cm in microwave dryer, is 2.45GHz ± 25MHz, temperature in microwave frequency
It is sterilized and is dried under the conditions of 60~80 DEG C of degree, 4~10min of time, moisture is less than 7wt% after drying；Then, it will dry
Material after dry and sterilizing crushes, and crosses 80 mesh and sieves to obtain fine powder；Finally, it is required fine powder according to functions of the state food technology
Capsule or tablet or electuary is made, is packed.
Embodiment 2
The present embodiment provides a kind of functional foods of protection and regulating gastointestinal function, in terms of mass parts, by following raw material
It is made：30 parts of orange peel extract, 30 parts of tuckahoe extracts, 15 parts of Fructus Amomi extract, 15 parts of haw thorn extract and pineapple extract
10 parts.Preparation method is the same as embodiment 1.
Embodiment 3
The present embodiment provides a kind of functional foods of protection and regulating gastointestinal function, in terms of mass parts, by following raw material
It is made：40 parts of orange peel extract, 20 parts of tuckahoe extracts, 15 parts of Fructus Amomi extract, 15 parts of haw thorn extract and pineapple extract
10 parts.Preparation method is the same as embodiment 1.
Embodiment 4
The present embodiment provides a kind of functional foods of protection and regulating gastointestinal function, in terms of mass parts, by following raw material
It is made：25 parts of orange peel extract, 35 parts of tuckahoe extracts, 15 parts of Fructus Amomi extract, 15 parts of haw thorn extract and pineapple extract
10 parts.Preparation method is the same as embodiment 1.
Embodiment 5
The present embodiment provides a kind of functional foods of protection and regulating gastointestinal function, in terms of mass parts, by following raw material
It is made：35 parts of orange peel extract, 30 parts of tuckahoe extracts, 10 parts of Fructus Amomi extract, 15 parts of haw thorn extract and pineapple extract
10 parts.Preparation method is the same as embodiment 1.
Embodiment 6
The present embodiment provides a kind of functional foods of protection and regulating gastointestinal function, in terms of mass parts, by following raw material
It is made：35 parts of orange peel extract, 35 parts of tuckahoe extracts, 15 parts of Fructus Amomi extract, 10 parts of haw thorn extract and pineapple extract 5
Part.Preparation method is the same as embodiment 1.
Comparative example 1
A kind of functional food of this comparative example offer is made in terms of mass parts by following raw material：50 parts of orange peel extract,
2 parts of 38 parts of tuckahoe extracts, 5 parts of Fructus Amomi extract, 5 parts of haw thorn extract and pineapple extract.The same embodiment of preparation method
1。
Comparative example 2
A kind of functional food of this comparative example offer is made in terms of mass parts by following raw material：5 parts of orange peel extract, Fu
5 parts of 5 parts of Siberian cocklebur extract, 50 parts of Fructus Amomi extract, 35 parts of haw thorn extract and pineapple extract.Preparation method is the same as embodiment 1.
Comparative example 3
A kind of functional food of this comparative example offer is made in terms of mass parts by following raw material：50 parts of orange peel extract,
10 parts of 20 parts of tuckahoe extracts, 20 parts of Fructus Amomi extract and pineapple extract.Preparation method is the same as embodiment 1.
Test example
Toxotest
Oral toxicity experiment, binomial mutagenicity test (mouse have been carried out to the functional food of the embodiment of the present invention 1~6
Polychromatic erythrocyte number micronucleus test and sperm malformation test) and 30 days feeding trials safety evaluatio experiment and disease
Tissue examination and gross anatomy experiment are managed, test data does not find that given the test agent has apparent toxic effect, by acute toxicity
Grade scale is evaluated, which belongs to nontoxic grade.
Functional experiment is tested
Efficacy test is carried out to the functional food of the embodiment of the present invention 1 and comparative example 1~3 respectively, including to rat stomach
Egg enzymatic activity influences experiment, tests influence experiment, the influence to mouse small intestine advancing movement that mouse glucose absorbs, is right
The influence experiment and mouse Hp infected gastric disease model experiments of mouse gastric emptying.
1 materials and methods
1.1 instruments and reagent
Test sample：The functional food of the embodiment of the present invention 1 is provided by Kazakhstan Foucault skill (Wuhan) Group Co., Ltd, rule
Lattice 0.5g/ pieces, human body recommended amounts 50mg/kg*d；The functional food of comparative example 1~3, specification 0.5g/ pieces.
NCTC16637 plants of bacterial strain Hp, Guangxi Medical University provide.
Reagent：Sanjiu weitai capsules, Sanjiu Pharmaceutical Co., Ltd's production, lot number：20161102, Chinese medicines quasi-word
Z44020705；Ranitidine Capsules, Weiqida Pharmaceutical Ind Co., Ltd. produce, Chinese medicines quasi-word 20161202；Fast urease
Kit (Fujian Sanqiang Biochemical Co., Ltd.)；Boric acid methylenum careuleum reagent, MaxVision Rapid Immuno group kits
(anti-mouse/rabbit igg polymer of peroxidase label), antigen retrieval trypsase (Trypsin) kit, DAB colour reagents
Box, antibody diluent (being purchased from Fuzhou Maixin biotechnology Development Co., Ltd)；Concentrated type rabbit-anti nNOS IgG, rabbit-anti iNOS
IgG (primary antibody) (is purchased from Wuhan doctor's moral company).
Instrument：A-1000S Rotary Evaporators, Japanese EYELA companies；AUW220 types electronic balance (Shanghai exact science instrument
Device Co., Ltd)；LG-2.4G supercentrifuges, Beijing Medical Centrifugal Machine Factory；Micropipettor, Shanghai big dragon Medical Devices have
Limit company；SN-695B types, which are intelligently put, exempts from γ measuring instruments, one factory of Shanghai nuclear research institute day ring instrument.
1.2 experimental animal
KM 18~22g of mouse weight, male and female dual-purpose, SD 180~220g of rat body weight, male and female dual-purpose are tested by Hubei Province
Animal center provides, cleaning grade.
1.3 experimental data statistical processing methods
Using the four fold table exact propability and Wilcoxon rank sum tests of 3.1 statistical softwares of PEMS to data at
Reason, with P<0.05 is statistically significant for difference.
2 experimental methods and result
The influence of 2.1 pairs of rat pepsin activities
Rat 80,180~220g of weight is divided 8 groups, every group 10 by weight at random.Respectively control group, embodiment 1
Basic, normal, high (0.5g/kg, the 1.0g/kg, 2.0g/kg) dosage group of functional food, sanjiu weitai capsules (3.0g/kg) group, comparative example 1
3 groups of group (1 functional food of 2.0g/kg comparative examples), 2 groups of comparative example (2 functional food of 2.0g/kg comparative examples) and comparative example
(3 functional food of 2.0g/kg comparative examples).Each group continuously gives respective relative medicine 5d, last dose after adaptability raising 3d
Preceding fasting is for 24 hours.Etherization cuts off osculum along rat abdomen median line, gently finds out stomach, ligatures pylorus, duodenal administration one
Secondary, suturing them notch takes out stitches after 5h and opens abdominal cavity ligation cardia, win full stomach, bloodstain is cleaned with filter paper, cut off along big curved side
Gastral cavity pours out gastric content, is collected in graduated centrifuge tube, records gastric juice amount.3000r/min centrifuges 15min, takes supernatant gastric juice
1mL is added phenolphthalein 1 and drips, and with 0.02mol/L sodium hydroxide titrations to not taken off in blush, calculates total acidity.Pepsin activity
It is carried out according to mettShi methods, pepsin activity is calculated by formula.Experimental result is shown in Table 1.
Total ml × 10 of sodium hydroxide of total acidity=titration consumption；
Total acid output μ Eq/h=total acidities × gastric juice hourly amount；
Pepsin activity unit=length average value2×16。
Influence result of 1 functional food of table to rat stomach egg enzymatic activity
Note：T inspections are carried out between group, compared with the control group,△Indicate P<0.05,△△Indicate P<0.01.
As shown in Table 1, the middle and high dosage group of 1 functional food of embodiment can substantially reduce gastric secretion and total acid discharge
Amount, significantly increases pepsin activity.
The influence experiment that 2.2 pairs of mouse glucoses absorb
Kunming mice 96,18~22g divides 8 groups, every group 12 by weight.Respectively control group, embodiment 1 are functional
Basic, normal, high (1.0g/kg, 2.0g/kg, the 4.0g/kg) dosage group of food, sanjiu weitai capsules (3.0g/kg) group, 1 group of comparative example
(functional food in 4.0g/kg comparative examples 1), 2 groups of comparative example (functional food in 4.0g/kg comparative examples 2) and comparison
3 groups of example (functional food in 4.0g/kg comparative examples 3).Daily gastric infusion 1 time, continuous 7d, overnight fasting, 8d mouse
Under urethane (2g/kg) anesthesia, one section of small intestine for starting about 6~8cm under pylorus at 2cm is detached, both ends are ligatured with silk thread, are tied
It pricks in small intestine and injects 10% glucose 0.3mL, reset wound, suturing them.Mouse is put to death after 30min, takes out the intestinal segment of ligation,
It is rinsed with distilled water 9mL, flushing liquor detaches 10min with 3000r/min, and supernatant is taken to measure glucose sugared content.By standard pipe
Sugared content subtracts the glucose that the sugared content in intestines is intestinal absorption, calculates the percentage of absorption.Experimental result is shown in Table 2.
The influence result that 2 functional food of table absorbs mouse glucose
| Group | Dosage (g/kg) | Glucose absorption (mmol/L) | Absorptivity (%) |
| Control group | 0 | 17.05±4.22 | 71.03±17.38 |
| High dose group | 4.0 | 18.80±3.92 | 78.21±16.61 |
| Middle dose group | 2.0 | 17.91±4.59 | 74.33±19.39 |
| Low dose group | 1.0 | 16.95±3.57 | 63.91±23.19 |
| Sanjiu weitai capsules | 6.0 | 19.89±2.67 | 86.21±10.47△ |
| 1 group of comparative example | 4.0 | 16.13±3.57 | 61.35±15.40 |
| 2 groups of comparative example | 4.0 | 16.25±3.69 | 62.35±17.26 |
| 3 groups of comparative example | 4.0 | 16.19±4.36 | 61.35±16.45 |
Note：T inspections are carried out between group, compared with the control group,△Indicate P<0.05,△△Indicate P<0.01.
As shown in Table 2,1 functional food Three doses of embodiment have no bright to absorption of glucose and absorption percentage
Development is rung.Sanjiu weitai capsules then significantly improve the absorptivity of glucose.
The influence experiment of 2.3 pairs of mouse small intestine advancing movements
Healthy 18~22g of Kunming mouse, 108, half male and half female.It is randomly divided into 9 groups, every group 12 by weight gender.
Respectively control group, basic, normal, high (1.0g/kg, 2.0g/kg, the 4.0g/kg) dosage group of 1 functional food of embodiment, three nine-day periods after the winter solstice stomach
Safe 6.0g/kg groups, atropine sulfate 5mL/kg groups, 1 group of comparative example (1 functional food of 4.0g/kg comparative examples), 2 groups of comparative example
(2 functional food of 4.0g/kg comparative examples) and 3 groups of comparative example (3 functional food of 4.0g/kg comparative examples).Sulfuric acid atropine
Outside group subcutaneous administrations, the equal gastric infusion of remaining each group.After 20min is subcutaneously injected, after gastric infusion 60min, every mouse
The commercially available prepared Chinese ink of 0.2mL is gavaged, 20min cervical dislocations put to death mouse.Abdominal cavity is dissected, the intestines of stomach to ileocecus are all taken out, it is light to spread
It is small intestine overall length on glass plate, measuring the distance from pylorus to ileocecus, promotes Front distance to be pushed away for small intestine from pylorus to prepared Chinese ink
Into distance, prepared Chinese ink ink propulsive rate is calculated.Experimental result is as shown in table 3.
Prepared Chinese ink ink propulsive rate (%)=prepared Chinese ink actuating length/total small intestinal length × 100% in the intestine
Influence result of 3 functional food of table to rat stomach egg enzymatic activity
Note：T inspections are carried out between group, compared with the control group,△Indicate P<0.05,△△Indicate P<0.01.
As shown in Table 3,1 functional food high dose group of embodiment can pole significantly improve the advancing movement of mouse small intestine, sulphur
Sour atropine then significantly inhibits intestinal motility.
The influence experiment of 2.4 pairs of mouse gastric emptying movements
18~22g of kunming mice, totally 96, half male and half female.It is randomly divided into 8 groups, every group 12 by weight gender.Respectively
Control group, basic, normal, high (1.0g/kg, 2.0g/kg, the 4.0g/kg) dosage group of 1 functional food of embodiment, sanjiu weitai capsules 6.0g/
Kg groups, 1 group of comparative example (1 functional food of 4.0g/kg comparative examples), 2 groups of comparative example (2 functional food of 4.0g/kg comparative examples)
With comparative example 3 groups (3 functional foods of 4.0g/kg comparative examples).Daily gastric infusion 1 time, continuous 5d, 1h, is incited somebody to action after the last administration
The 5% Arabic gum 0.8g of mouse gavaging of fasting 18h.After gavage 20min, put to death mouse on time, dissection take out stomach together with
Content is weighed, and then cuts off stomach along greater curvature, rinses content, and filter paper suck dry moisture claims stomach net weight, the two difference to be stomach
Retention value, it is gastric emptying amount to subtract retention value with 0.8g.The results are shown in Table 4.
Influence result of 4 functional food of table to mouse gastric emptying
| Group | Dosage (g/kg) | Gastric emptying amount (g) | With control group than increase and decrease (%) |
| Control group | 0 | 0.49±0.12 | / |
| High dose group | 4.0 | 0.39±0.19 | -18.73 |
| Middle dose group | 2.0 | 0.55±0.16 | +14.59 |
| Low dose group | 1.0 | 0.60±0.15△ | +25.01△ |
| Sanjiu weitai capsules | 6.0 | 0.36±0.13 | -25.00 |
| 1 group of comparative example | 4.0 | 0.45±0.17 | -5.31 |
| 2 groups of comparative example | 4.0 | 0.46±0.12 | -5.26 |
| 3 groups of comparative example | 4.0 | 0.45±0.18 | -5.32 |
Note：T inspections are carried out between group, compared with the control group,△Indicate P<0.05,△△Indicate P<0.01.
As shown in Table 4,1 functional food low dose group of embodiment is remarkably improved gastric emptying amount, sanjiu weitai capsules and remaining
Two dosage groups have no mouse gastric emptying amount and significantly affect.
2.5 mouse Hp infected gastric disease model experiments
Animal model：Cleaning grade BALB/c mouse 96, weight (20 ± 2) g, be randomly divided into 2 batches (be respectively 7d with
28d), 4 groups of every batch of:Blank control group, positive controls, 1 functional food group of embodiment, ranitidine group, every group 12.It makes
Before mould, gentamicin sulphate 15mg/ (kg*d), ampicillin sodium 10mg/ (kg*d) are added in mouse drinking water, it is small to remove
Miscellaneous bacteria in mouse stomach starts modeling after continuous 5d, drug withdrawal 5d.1d before gavage Hp, in addition to blank control group, remaining group mouse (with
Lower abbreviation modeling group) with 50% alcohol 0.12mL/20g gavages 1 time.Modeling starts, and modeling group gavage Hp a concentration of 1 ×
109The improved broth medium of CFU/mL, blank control group gavage be free of Hp improved broth medium, each 0.4mL/ only, the next day 1
It is secondary, totally 5 times.Fasting before gavage prohibits water for 24 hours, and water 4h is prohibited in fasting after gavage.2d starts to be administered after modeling:Blank control group and
Positive controls gavage physiological saline, 1 functional food group gavage 1 functional food suspension of embodiment of embodiment are (a concentration of
2.0g/mL), ranitidine group gavage ranitidine solution (a concentration of 18.75mg/mL), each 0.4mL/, one time a day, continuously
7d or 28d.
Execution and pathological staining：2 batches of mouse are put to death in dislocation of cervical vertebra method in 8d, 29d, mouse fasting, taboo before putting to death
Water is for 24 hours.Pincers take a fritter mucous membrane at the nearly pylorus in lesser curvature side to do rapid urease test.It is small curved from cardia to pylorus longitudinal direction clip
Side holostrome tissue, is fixed for 24 hours with 10% formalin, and routine paraffin wax embedding, slice carry out Hp specific stain (boric acid methylenum careuleum
Method), HE dyeing and immunohistochemical staining (MaxVision Rapid Immunos histochemical staining method/two step method), operating method reference
Related kit specification.
Observed content
(1) Hp infection conditions:Rapid urease test and Hp specific stains two are positive just positive for Hp.
As a result Hp number positives and positive rate：1 functional food group 7d, 28d two batches Hp positive rates of embodiment (38.5%,
15.4%) there is highly significant sex differernce (P compared with positive controls (100%, 76.9%)<0.01)；With ranitidine group
(84.6%, 69.2%) more significant difference (P<0.05), the difference compared with blank control group (0%, 0%)
(0.01<P<0.05) or it is not statistically significant.
(2) stomach lining degree of inflammation:Classification (2000 year national chronic gastritis discussion of the gastritis of mouse with reference to people's gastritis
Sorting technique in meeting National Consensus), chronic superficial gastritis is belonged to, according to the quantity of inflammatory cell and the depth of infiltration stomach wall
It is divided into 3 grades and scores:No inflammation 0 is divided, and mild inflammation 1 divides, and moderate inflammation 2 divides, and hyperphlogosis 3 divides.It the results are shown in Table 5 and table 6.
5 each group stomach lining degree of inflammation of table compares (7d)
| Group | Without (0) | Slightly (1) | Moderate (2) | Severe (3) |
| Blank control group | 6 | 5 | 1 | 0 |
| Positive controls | 0 | 2 | 5 | 5 |
| 1 functional food group * of embodiment | 1 | 7 | 4 | 0 |
| Ranitidine group | 0 | 3 | 5 | 4 |
Note：Compared with blank control group, 0.01<*P<0.05；Compared with positive controls, * P<0.01；With ranitidine
Group compares, * P<0.05.
6 each group stomach lining degree of inflammation of table compares (28d)
| Group | Without (0) | Slightly (1) | Moderate (2) | Severe (3) |
| Blank control group | 8 | 4 | 0 | 0 |
| Positive controls | 0 | 1 | 4 | 7 |
| 1 functional food group * of embodiment | 5 | 6 | 1 | 0 |
| Ranitidine group | 1 | 7 | 3 | 1 |
Note:Compared with blank control group, * P>0.05；Compared with positive controls, * P<0.05；With ranitidine group ratio
Compared with * P<0.05.
By table 5 and table 6 it is found that 1 functional food 7d, 28d two batches of embodiment are compared with positive controls, stomach lining inflammation
Degree has highly significant or significant difference；With the more significant difference of ranitidine group；Relatively have with blank control group
Institute's difference is not statistically significant；And treat 7d stomach lining inflammation improvements by 1 functional food of embodiment treatment 28d ratios
It is good.
(3) nNOS, iNOS expression intensity:NNOS, iNOS immune group are observed using semiquantitative method is estimated under light microscope
Change the positive findings of stained slice.Standards of grading：Positive degree：Non-coloring is 0, and light yellow is 1, yellow 2, brown color, palm fibre
Brown is 3；Positive range：Non-coloring is 0, coloring<30% is 1, coloring>30% is 2, diffuses and is colored as 3.Every slice exists
5 visuals field of random observation, take its mean score under 200 power microscopes.Above-mentioned two results addeds, 0~1 point for-, 2 points are
+, 3~4 points are ++, 5~6 points are +++.It the results are shown in Table 7 and table 8.
7 each group nNOS, iNOS expression intensity (7d) of table
Note：Compared with blank control group, * P>0.05；Compared with positive controls, * P<0.01(nNOS),*P<0.05
(iNOS)；Compared with ranitidine group, * P<0.05.
8 each group nNOS, iNOS expression intensity (28d) of table
Note：Compared with blank control group, * P>0.05；Compared with positive controls, * P<0.01；With ranitidine group ratio
Compared with * P<0.05.
By table 7 and table 8 it is found that the expression intensity and positive controls of functional food group 7d, 28d two batches nNOS, iNOS
Comparing has highly significant or significant difference；With the more significant difference of ranitidine group；The nothing compared with blank control group
Statistical significance；And 28d is treated compared with treating 7d by 1 functional food of embodiment, nNOS expression intensities are in highly significant
Property decline, iNOS expression intensities in conspicuousness decline.
In conjunction with observed content as a result, mouse Hp infected gastric disease model experiment results show:The function of the embodiment of the present invention
Property food can significantly reduce the positive rate of Hp, mitigate stomach lining degree of inflammation, reduce nNOS, iNOS expression intensity, reduce NO's
A large amount of damaging actions generated to stomach lining to play the protective effect to stomach lining, and treat 28d ratios and treat 7d effects
It is good.
In conclusion the functional food of the present invention can enhance gastric mucosal barrier ability by adjusting body's immunity,
Gastric acid secretion inhibiting adjusts microenvironment in stomach, inhibits Hp, improves Gastric Mucosa Blood Flow, inhibit pro-inflammatory cytokine, mitigates mycogastritis
Disease enhances peptic activity of stomach, promotes digestion, gastric emptying ability is improved, to realize protection and regulating gastointestinal function.
Finally, method of the invention is only preferable embodiment, is not intended to limit the scope of the present invention.It is all
Within the spirit and principles in the present invention, any modification, equivalent replacement, improvement and so on should be included in the protection of the present invention
Within the scope of.
Claims (9)
1. a kind of functional food of protection and regulating gastointestinal function, which is characterized in that in terms of mass parts, by including following components
Raw material be made：10~40 parts of orange peel extract, 10~40 parts of tuckahoe extracts, 10~30 parts of Fructus Amomi extract, hawthorn extraction
5~20 parts of 10~30 parts of object and pineapple extract.
2. functional food according to claim 1, which is characterized in that in terms of mass parts, by the original including following components
Material is made：20~40 parts of orange peel extract, 20~40 parts of tuckahoe extracts, 15~25 parts of Fructus Amomi extract, haw thorn extract 10
~20 parts and 5~10 parts of pineapple extract.
3. functional food according to claim 2, which is characterized in that in terms of mass parts, by the original including following components
Material is made：25~35 parts of orange peel extract, 25~35 parts of tuckahoe extracts, 18~22 parts of Fructus Amomi extract, haw thorn extract 10
~13 parts and 8~13 parts of pineapple extract.
4. according to claims 1 to 3 any one of them functional food, which is characterized in that the raw material by orange peel extract,
Tuckahoe extracts, Fructus Amomi extract, haw thorn extract and pineapple extract composition.
5. according to Claims 1 to 4 any one of them functional food, which is characterized in that the dosage form of the functional food
For capsule, tablet or electuary.
6. the preparation method of Claims 1 to 5 any one of them functional food, which is characterized in that including：Each component is pressed
Proportioning is mixed, is dried, is sterilized, crushed and is crossed 60~100 mesh sieve, and target formulation finally is made in sieving gained fine powder.
7. preparation method according to claim 6, which is characterized in that each component mixed, dry after water content
For 4wt%~7wt%.
8. preparation method according to claim 6, which is characterized in that the drying and the sterilizing are in microwave frequency
2.45GHz ± 25MHz, temperature carry out under the conditions of being 60~80 DEG C.
9. preparation method according to claim 6, which is characterized in that the sieving was 80 mesh sieve.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810509234.7A CN108783456A (en) | 2018-05-24 | 2018-05-24 | A kind of functional food and preparation method thereof of protection and regulating gastointestinal function |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810509234.7A CN108783456A (en) | 2018-05-24 | 2018-05-24 | A kind of functional food and preparation method thereof of protection and regulating gastointestinal function |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108783456A true CN108783456A (en) | 2018-11-13 |
Family
ID=64092894
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810509234.7A Pending CN108783456A (en) | 2018-05-24 | 2018-05-24 | A kind of functional food and preparation method thereof of protection and regulating gastointestinal function |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108783456A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109662317A (en) * | 2019-01-14 | 2019-04-23 | 王巧云 | A kind of composition and its application method for stomach conditioning health |
| CN110236034A (en) * | 2019-06-26 | 2019-09-17 | 佛山市绿康宝保健食品有限公司 | A kind of herbal composite for coordinating intestines and stomach |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1742971A (en) * | 2005-09-17 | 2006-03-08 | 张志祥 | Instant preparation of Fructus sea semen Amomi and hawthorn and preparing process |
| KR100692175B1 (en) * | 2005-03-25 | 2007-03-12 | 손병국 | Health functional food having an energetic and sturdy action |
| CN104720040A (en) * | 2015-03-05 | 2015-06-24 | 广西大学 | Health drink for treating chronic gastroenteritis and production method of health drink for treating chronic gastroenteritis |
-
2018
- 2018-05-24 CN CN201810509234.7A patent/CN108783456A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100692175B1 (en) * | 2005-03-25 | 2007-03-12 | 손병국 | Health functional food having an energetic and sturdy action |
| CN1742971A (en) * | 2005-09-17 | 2006-03-08 | 张志祥 | Instant preparation of Fructus sea semen Amomi and hawthorn and preparing process |
| CN104720040A (en) * | 2015-03-05 | 2015-06-24 | 广西大学 | Health drink for treating chronic gastroenteritis and production method of health drink for treating chronic gastroenteritis |
Non-Patent Citations (2)
| Title |
|---|
| 杨钧: "倒卵叶五加对胃肠功能的实验研究", 《陕西中医》 * |
| 辛敏等: "七方胃痛颗粒对Hp感染性胃病小鼠的疗效及其对NOS的影响", 《江苏中医药》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109662317A (en) * | 2019-01-14 | 2019-04-23 | 王巧云 | A kind of composition and its application method for stomach conditioning health |
| CN110236034A (en) * | 2019-06-26 | 2019-09-17 | 佛山市绿康宝保健食品有限公司 | A kind of herbal composite for coordinating intestines and stomach |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110447902B (en) | Composition with weight-losing effect | |
| CN108783456A (en) | A kind of functional food and preparation method thereof of protection and regulating gastointestinal function | |
| CN101554362A (en) | Composition of natural product and preparation thereof | |
| US10485834B2 (en) | Chinese herbal oral paste for conditioning phlegm-dampness constitution and processing method thereof | |
| CN105943958A (en) | Inonotus obliquus composite solid particles for treating gout and preparing method thereof | |
| CN106173450A (en) | Improve compound feed additive and the feedstuff of pigeon immunity | |
| CN105535859A (en) | Traditional Chinese medicine preparation for treating stomach cancer and preparing method thereof | |
| CN103920140B (en) | A kind of people is with blood sugar lowering Weight-reducing and lipid-lowering compound preparation | |
| CN110024941A (en) | A kind of composition and its application with blood-enrich function | |
| CN105194225A (en) | Traditional Chinese medicine for treatment of children iron deficiency anemia | |
| CN108567875A (en) | A kind of Chinese medicine composition and its Chinese medicine preparation for treating salpingitis of layer chicken | |
| CN105028995A (en) | Mixed dog food and preparation method thereof | |
| CN114522183A (en) | Sea cucumber extract for increasing bone mineral density | |
| CN104666475B (en) | A kind of Chinese goldthread colla corii asini composition for treating dry syndrome and its application | |
| CN100536905C (en) | Chinese-medicinal composition for treating stomachalgia | |
| CN110236035A (en) | A kind of Wolfberry hawthron health care magma and its application | |
| CN104491338B (en) | A kind of medicine-food dual-purpose composition to relax bowel and preparation method thereof | |
| CN108524713A (en) | Improve the functional composition and its preparation method and application of male prostate health | |
| CN107496532A (en) | A kind of Chinese medicine composition for treating chicken dysentery and preparation method thereof | |
| CN106822223A (en) | A kind of astragalus polyose Radix Angelicae Sinensis polysaccharide composition iron supplementary and preparation method and application | |
| CN102579713B (en) | Traditional Chinese medicine for treating children obesity and preparation method | |
| CN107320547B (en) | A kind of drug and preparation method thereof for treating the cancer of the esophagus | |
| CN106389647A (en) | Medicine for treating blood diseases | |
| CN106361938A (en) | Traditional Chinese medicine composition for preventing and treating chicken infectious anemia and preparation method and application thereof | |
| CN1166383C (en) | Medicine for treating tumor in digestive tract and its prepn |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20181113 |